NO20050018L - Lasofoxifentabletter og belegg - Google Patents

Lasofoxifentabletter og belegg

Info

Publication number: NO20050018L
Authority: NO; Norway
Prior art keywords: lasofoxifene; tablets; coatings; active ingredient; triacetin
Prior art date: 2002-07-10

Application number

NO20050018A

Other languages

English (en)

Norwegian (no)

Inventor

Daniel Scott Gierer

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-10

Filing date

2005-01-03

Publication date

2005-01-12

2005-01-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-01-12 Publication of NO20050018L publication Critical patent/NO20050018L/no

Links

GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title abstract 3
229960002367 lasofoxifene Drugs 0.000 title abstract 3
238000000576 coating method Methods 0.000 title 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 2
238000009513 drug distribution Methods 0.000 abstract 1
235000013773 glyceryl triacetate Nutrition 0.000 abstract 1
239000001087 glyceryl triacetate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000004014 plasticizer Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
239000000377 silicon dioxide Substances 0.000 abstract 1
229960002622 triacetin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20050018A 2002-07-10 2005-01-03 Lasofoxifentabletter og belegg NO20050018L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39509002P	2002-07-10	2002-07-10
PCT/IB2003/003074 WO2004006895A1 (fr)	2002-07-10	2003-06-30	Comprime de lasofoxifene et enrobage de celui-ci

Publications (1)

Publication Number	Publication Date
NO20050018L true NO20050018L (no)	2005-01-12

Family

ID=30115812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20050018A NO20050018L (no)	2002-07-10	2005-01-03	Lasofoxifentabletter og belegg

Country Status (35)

Country	Link
US (2)	US20040057992A1 (fr)
EP (1)	EP1534248B1 (fr)
JP (2)	JP4446446B2 (fr)
KR (1)	KR100782693B1 (fr)
CN (1)	CN100344278C (fr)
AP (1)	AP2005003201A0 (fr)
AR (1)	AR040434A1 (fr)
AT (1)	ATE550017T1 (fr)
AU (1)	AU2003247017B2 (fr)
BR (1)	BR0312563A (fr)
CA (1)	CA2489407C (fr)
CY (1)	CY1112892T1 (fr)
DK (1)	DK1534248T3 (fr)
EA (1)	EA007268B1 (fr)
EC (1)	ECSP055528A (fr)
ES (1)	ES2395123T3 (fr)
HN (1)	HN2003000206A (fr)
HR (1)	HRP20041196A2 (fr)
IL (2)	IL165746A0 (fr)
IS (1)	IS7594A (fr)
MA (1)	MA27318A1 (fr)
MX (1)	MXPA05000394A (fr)
NO (1)	NO20050018L (fr)
NZ (1)	NZ537278A (fr)
OA (1)	OA12883A (fr)
PA (1)	PA8576201A1 (fr)
PE (1)	PE20040104A1 (fr)
PL (1)	PL374913A1 (fr)
PT (1)	PT1534248E (fr)
SI (1)	SI1534248T1 (fr)
TN (1)	TNSN05006A1 (fr)
TW (1)	TW200406222A (fr)
UY (1)	UY27886A1 (fr)
WO (1)	WO2004006895A1 (fr)
ZA (1)	ZA200410196B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) *	2003-06-12	2004-12-16	Luner Paul E.	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
WO2006105806A1 (fr) *	2005-04-07	2006-10-12	Miso Sabovic	Retardement du processus de vieillissement et des troubles provoques par le vieillissement
CN101198319B (zh) *	2005-04-26	2012-08-01	大日本住友制药株式会社	含有双胍化合物的颗粒制剂
GB0516604D0 (en) *	2005-08-12	2005-09-21	Sandoz Ag	Rapidly dispersing/disintegrating compositions
JP5688877B2 (ja)	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
MX2009008935A (es)	2007-02-23	2009-11-02	Gilead Sciences Inc	Moduladores de las propiedades farmacocineticas de productos terapeuticos.
CA2835910C (fr) *	2007-04-25	2016-06-28	Warner Chilcott Company, Llc	Uniformite amelioree de contenu de vitamine d dans des formes dosifiees pharmaceutiques
US20100055180A1 (en) *	2007-10-10	2010-03-04	Mallinckrodt Baker, Inc.	Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
SG185257A1 (en) *	2007-10-10	2012-11-29	Avantor Performance Mat Inc	Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20090274757A1 (en) *	2008-05-01	2009-11-05	Wyeth	Pharmaceutical polish formulations
MX2010011963A (es)	2008-05-02	2010-12-06	Gilead Sciences Inc	Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
PT2451445T (pt) *	2009-07-06	2019-07-10	Boehringer Ingelheim Int	Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
HUE051585T2 (hu) *	2011-10-17	2021-03-01	Lexicon Pharmaceuticals Inc	(S)-etil-2-amino-3-(4-(2-amino-6-((R)-1-(4-klór-2-(3-metil-1H-pirazol-1-il)fenil)-2,2,2- trifluoretoxi)pirimidin-4-il)fenil)propanoát szilárd adagolási formái
DK2851075T3 (da)	2012-05-14	2022-01-31	Shionogi & Co	Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
EP3043778B1 (fr) *	2013-09-13	2017-09-06	Bayer Pharma Aktiengesellschaft	Compositions pharmaceutiques contenant du refametinib
RU2539375C1 (ru) *	2013-11-07	2015-01-20	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) *	2014-03-14	2014-06-04	王志刚	一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh)	2014-08-26	2016-06-01	財團法人工業技術研究院	剪切增稠配方、及包含其之複合材料
CN105434444B (zh) *	2014-09-29	2021-02-05	上海奥奇医药科技有限公司	一种A-失碳-5α雄甾烷化合物的口服制剂
MX382609B (es) *	2016-07-25	2025-03-13	Canopy Growth Corp	Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
ES2909576T3 (es)	2016-10-11	2022-05-09	Univ Duke	Tratamiento con lasofoxifeno del cáncer de mama ER+
US11497730B2 (en)	2018-04-10	2022-11-15	Duke University	Lasofoxifene treatment of breast cancer
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) *	2022-02-18	2022-04-08	山东新时代药业有限公司	一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4182A (en) *		1845-09-09		Island
US4880636A (en) *	1988-05-13	1989-11-14	Franz Robert M	Film coated tablet of ranitidine HCl
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) *	1995-11-02	2002-12-16	Пфайзер Інк.	(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
US6372457B1 (en)	1997-01-14	2002-04-16	Arkion Life Sciences Llc	Process and materials for production of glucosamine
KR200161927Y1 (ko) *	1997-08-26	1999-12-01	윤종용	냉장고
YU26700A (sh) *	1999-05-24	2002-06-19	Pfizer Products Inc.	Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) *	1999-09-29	2002-08-20	Pfizer Inc.	Dosing regimens for lasofoxifene
US6419956B1 (en) *	1999-12-30	2002-07-16	Ancile Pharmaceuticals	Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (fr) *	2000-03-10	2001-11-14	Pfizer Products Inc.	Utilisation d'un sel ferreux pour l'inhibition de la dégradation oxydative de compositions pharmaceutiques
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
JP2004531537A (ja) *	2001-05-01	2004-10-14	ファイザー・プロダクツ・インク	一様な薬剤分布と効力を有する低用量製薬組成物の製造方法
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

2003
- 2003-06-23 PA PA20038576201A patent/PA8576201A1/es unknown
- 2003-06-30 AU AU2003247017A patent/AU2003247017B2/en not_active Ceased
- 2003-06-30 PL PL03374913A patent/PL374913A1/xx not_active Application Discontinuation
- 2003-06-30 MX MXPA05000394A patent/MXPA05000394A/es active IP Right Grant
- 2003-06-30 SI SI200332150T patent/SI1534248T1/sl unknown
- 2003-06-30 PT PT03764059T patent/PT1534248E/pt unknown
- 2003-06-30 OA OA1200500007A patent/OA12883A/en unknown
- 2003-06-30 EA EA200401583A patent/EA007268B1/ru not_active IP Right Cessation
- 2003-06-30 WO PCT/IB2003/003074 patent/WO2004006895A1/fr not_active Ceased
- 2003-06-30 NZ NZ537278A patent/NZ537278A/en unknown
- 2003-06-30 KR KR1020057000369A patent/KR100782693B1/ko not_active Expired - Fee Related
- 2003-06-30 DK DK03764059.6T patent/DK1534248T3/da active
- 2003-06-30 AT AT03764059T patent/ATE550017T1/de active
- 2003-06-30 JP JP2004521001A patent/JP4446446B2/ja not_active Expired - Fee Related
- 2003-06-30 IL IL16574603A patent/IL165746A0/xx unknown
- 2003-06-30 EP EP03764059A patent/EP1534248B1/fr not_active Expired - Lifetime
- 2003-06-30 AP AP2005003201A patent/AP2005003201A0/xx unknown
- 2003-06-30 CA CA002489407A patent/CA2489407C/fr not_active Expired - Fee Related
- 2003-06-30 ES ES03764059T patent/ES2395123T3/es not_active Expired - Lifetime
- 2003-06-30 CN CNB038162881A patent/CN100344278C/zh not_active Expired - Fee Related
- 2003-06-30 BR BR0312563-7A patent/BR0312563A/pt not_active IP Right Cessation
- 2003-06-30 HR HR20041196A patent/HRP20041196A2/hr not_active Application Discontinuation
- 2003-07-01 US US10/612,679 patent/US20040057992A1/en not_active Abandoned
- 2003-07-04 TW TW092118389A patent/TW200406222A/zh unknown
- 2003-07-07 PE PE2003000682A patent/PE20040104A1/es not_active Application Discontinuation
- 2003-07-07 HN HN2003000206A patent/HN2003000206A/es unknown
- 2003-07-08 UY UY27886A patent/UY27886A1/es not_active Application Discontinuation
- 2003-07-08 AR AR20030102454A patent/AR040434A1/es not_active Application Discontinuation
2004
- 2004-12-13 IL IL165746A patent/IL165746A/en active IP Right Grant
- 2004-12-13 IS IS7594A patent/IS7594A/is unknown
- 2004-12-17 ZA ZA200410196A patent/ZA200410196B/en unknown
2005
- 2005-01-03 NO NO20050018A patent/NO20050018L/no not_active Application Discontinuation
- 2005-01-10 MA MA28036A patent/MA27318A1/fr unknown
- 2005-01-10 TN TNP2005000006A patent/TNSN05006A1/fr unknown
- 2005-01-10 EC EC2005005528A patent/ECSP055528A/es unknown
2006
- 2006-11-09 JP JP2006303440A patent/JP2007031451A/ja active Pending
- 2006-12-22 US US11/615,511 patent/US7553500B2/en not_active Expired - Fee Related
2012
- 2012-06-06 CY CY20121100504T patent/CY1112892T1/el unknown

Also Published As

Publication number	Publication date
SI1534248T1 (sl)	2012-07-31
JP2005535671A (ja)	2005-11-24
EA007268B1 (ru)	2006-08-25
NZ537278A (en)	2007-07-27
WO2004006895A1 (fr)	2004-01-22
US20040057992A1 (en)	2004-03-25
EA200401583A1 (ru)	2005-06-30
TW200406222A (en)	2004-05-01
EP1534248A1 (fr)	2005-06-01
HK1077747A1 (en)	2006-02-24
IL165746A0 (en)	2006-01-15
KR20050017102A (ko)	2005-02-21
AR040434A1 (es)	2005-04-06
ECSP055528A (es)	2005-03-10
TNSN05006A1 (fr)	2007-05-14
KR100782693B1 (ko)	2007-12-07
ATE550017T1 (de)	2012-04-15
IL165746A (en)	2008-12-29
CN100344278C (zh)	2007-10-24
PA8576201A1 (es)	2004-05-26
BR0312563A (pt)	2005-04-19
PL374913A1 (en)	2005-11-14
AU2003247017B2 (en)	2008-03-06
CA2489407C (fr)	2009-01-27
CY1112892T1 (el)	2016-04-13
IS7594A (is)	2004-12-13
PE20040104A1 (es)	2004-02-27
JP4446446B2 (ja)	2010-04-07
UY27886A1 (es)	2004-02-27
ZA200410196B (en)	2006-07-26
PT1534248E (pt)	2012-05-25
AP2005003201A0 (en)	2005-03-31
EP1534248B1 (fr)	2012-03-21
JP2007031451A (ja)	2007-02-08
ES2395123T3 (es)	2013-02-08
HN2003000206A (es)	2004-07-27
CA2489407A1 (fr)	2004-01-22
MXPA05000394A (es)	2005-03-23
DK1534248T3 (da)	2012-06-25
MA27318A1 (fr)	2005-05-02
US20070110800A1 (en)	2007-05-17
CN1668285A (zh)	2005-09-14
US7553500B2 (en)	2009-06-30
AU2003247017A1 (en)	2004-02-02
HRP20041196A2 (en)	2005-04-30
OA12883A (en)	2006-09-15

Legal Events

Date	Code	Title	Description
2013-10-07	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20050018L (no)	2005-01-12	Lasofoxifentabletter og belegg
TW200745111A (en)	2007-12-16	New compounds
MX2009006401A (es)	2009-06-23	Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
NO20062884L (no)	2006-08-18	AKT-proteinkinaseinhibitorer
NO20073959L (no)	2007-09-27	Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
TW200621762A (en)	2006-07-01	Novel compounds
NO20092737L (no)	2009-09-18	Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
WO2005005414A3 (fr)	2005-04-21	Derives de pyrazolyl-indole actifs en tant qu'inhibiteurs de kinase, procede de preparation correspondant et compositions pharmaceutiques les contenant
NO20011721D0 (no)	2001-04-05	N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
WO2001087839A8 (fr)	2004-04-08	Derives de piperidine pharmaceutiquement actifs, en particulier sous forme de modulateurs de l'activite des recepteurs de chimiokine
NO20070576L (no)	2007-04-10	Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
WO2023205463A8 (fr)	2024-03-28	Composés hétéroaryles pour le traitement de la douleur
NO20070570L (no)	2007-04-10	Forbindelser.
DE602004011966D1 (en)	2008-04-03	Heterocyclylverbindungen
BRPI0413438A (pt)	2006-10-17	derivados de pirimidilpirrol ativos como inibidores de cinase
ZA202501471B (en)	2025-10-29	Preparation and use of quinazolinone derivative as kinase inhibitor
WO2003057150A3 (fr)	2006-06-08	Formulation pharmaceutique d'hydrochlorure stable et procédé de préparation
NO20020282L (no)	2002-03-21	Nytt difenyl-piperidinderivat
NO20064010L (no)	2006-09-25	Indazolderivater og farmasoytiske preparater inneholdelse slike
WO2022106902A3 (fr)	2022-08-11	Dérivés de benzènesulfonamide et leurs utilisations
IL151359A0 (en)	2003-04-10	Esmolol formulation
WO2001000617A3 (fr)	2001-03-01	Nouveaux derives de piperazinyl-alkyl-thiopyrimidine compositions pharmaceutiques les contenant et procede de preparation de la substance active
UA90285C2 (ru)	2010-04-26	Производные гидантоина, полезные как ингибиторы металлопротеиназ
TW200606164A (en)	2006-02-16	New compounds
MXPA05012679A (es)	2006-02-08	Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.